Neuropathic Pain – Landscape & Forecast – Disease Landscape & Forecast

The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. Despite the increasing availability of generic analgesics from these drug classes, as well as the continued entrenchment of select therapies as key treatment options for neuropathic pain, unmet need for new analgesics—particularly those with novel mechanisms of action—remains, driven by the growing prevalence of the neuropathic pain patient population and the sizable percentage of patients refractory to current treatment.

Questions Answered:

  • What is the current state of treatment for neuropathic pain? What are interviewed experts’ opinions of current treatment options?
  • What are interviewed experts’ views on late-phase emerging therapies such as Pfizer / Eli Lilly’s tanezumab, Regeneron / Teva / Mitsubishi Tanabe Pharma’s fasinumab, Grünenthal’s cebranopadol, and Daiichi Sankyo’s mirogabalin as potential treatments for neuropathic pain?
  • What is the commercial potential of late-phase analgesic products in the neuropathic pain market should they launch?
  • How will the neuropathic pain therapy market evolve over the next decade in light of expanding generic competition and the entrance of new treatments through 2028?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neuropathic pain experts, pain specialists, and neurologists. Supported by survey data collected for other DRG research.

Epidemiology: Prevalence of neuropathic back pain, painful diabetic neuropathy, neuropathic cancer pain, and HIV/AIDS-related neuropathic pain by country; diagnosed prevalence of postherpetic neuralgia by country.

Forecast:Ten-year, top-down sales of key neuropathic pain therapies through 2028. Market segmentation of select neuropathic pain populations in the forecast base year (2018).

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 15 drugs.

launch Related Market Assessment Reports